DARE DARE BIOSCIENCE INC Expansion Plans 8-K Filing 2024 - Funding Agreement DARE Bioscience, Inc. has entered into a subaward agreement to receive up to $10 million for its DARE-HPV program, aimed at treating HPV-related cervical diseases, with a performance period of 24 months.Get access to all SEC 8-K filings of the DARE BIOSCIENCE INC